US Stock MarketDetailed Quotes

ELTX Elicio Therapeutics

Watchlist
  • 5.150
  • +0.080+1.58%
Close Dec 27 16:00 ET
55.58MMarket Cap-1.19P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Trytosaveabit
    Trytosaveabit
    Dec 12 06:13
    Update
    $Elicio Therapeutics (ELTX.US)$ Elicio Therapeutics Presents Updated Results From ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
    GlobeNewswire· 12 mins ago
    Updated Phase 1 data include a 16.3-month median recurrence-free survival ("mRFS") and 28.9-month median overall survival ("mOS") from full study population
    Strong correlation observed between mRFS and strength of T cell response
    Event-driven interim analysis from randomized Phase 2 trial expected in H1 2025
    Jaguar8
    Jaguar8
    Dec 12 06:04
    NEWS
    $Elicio Therapeutics (ELTX.US)$
    Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
    Thursday, 12th December at 7:00 am
    Updated Phase 1 data include a 16.3-month median recurrence-free survival ("mRFS") and 28.9-month median overall survival ("mOS") from full study population
    Strong correlation observed between mRFS and strength of T cell response
    Event-driven interim analysis from randomized Phase 2 trial expected in H1 20...
    Jaguar8
    Jaguar8
    Dec 3 06:05
    NEWS
    $Elicio Therapeutics (ELTX.US)$
    Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment
    Tuesday, 3rd December at 7:00 am
    BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ: ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the completion of enrollment in the Phase 2 AMPLIFY-7P study (NCT05726864). The randomized Phase 2 st...
    Jaguar8
    Jaguar8
    Nov 7 15:06
    NEWS
    $Elicio Therapeutics (ELTX.US)$
    Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting
    Elicio Therapeutics presented updated preliminary results from the AMPLIFY-7P Phase 1 clinical trial of ELI-002, an Amphiphile cancer vaccine targeting KRAS-mutant tumors. Key findings show mKRAS-specific T cell responses in all evaluable patients, with the 4.9 mg dose group showing 12-fold higher ...
    Jaguar8
    Jaguar8
    Oct 31 07:34
    NEWS
    $Elicio Therapeutics (ELTX.US)$
    Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
    Elicio Therapeutics (Nasdaq: ELTX) announced two upcoming presentations in November 2024. At the SITC 39th Annual Meeting (Nov 6-10), they will present updated T cell and Disease-Free Survival data from the AMPLIFY-7P Phase 1 trial of ELI-002, an Amphiphile cancer vaccine targeting KRAS-mutant tumor...
Read more
Heat List
US
Overall
Symbol
Price
% Chg

No Data